SAN FRANCISCO, Nov. 16, 2015 /PRNewswire/ -- The American Association for the Study of Liver Diseases (AASLD) issued the following statement during The Liver Meeting® being held this weekend in San Francisco and attracting about 10,000 of the leading liver specialists in the world: Over the past two-plus years, the Food and Drug Administration has approved multiple new treatments for hepatitis C virus (HCV) that offer nearly universal cure rates with minimal side effects. It is a remarkable success story for medical science. Unfortunately, many insurers – both private and public – are delaying...
↧